You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾迪藥業(688488.SH):與韓國Kainos簽訂合作備忘錄
格隆匯 11-22 15:05

格隆匯 11 月 22日丨艾迪藥業(688488.SH)公佈,公司近日與韓國康佳諾醫療科技發展有限公司(Kainos Medicine Inc. , 以下簡稱"Kainos")簽署了《Memorandumof Understanding》(《合作備忘錄》,以下簡稱"備忘錄")。

根據備忘錄,甲乙雙方擬以現金出資方式按 55:45 的比例於新加坡設立合資公司,出資總額為 50 萬新幣。合資公司將致力於在全球市場(不含中國與韓國)開展醫療健康項目及相關產品的合作、專利授權和商業化活動。甲方擬將其擁有的 ACC007、ACC010 和 ACC015(以下合稱"產品")的海外權利(不含韓國、中國大陸、香港及台灣)獨家授予合資公司;乙方擬將其擁有的產品臨牀研究數據的使用權利獨家授予合資公司。

公告稱,此次備忘錄的簽署預計不會對公司 2020 年度的經營業績產生重大影響。公司與 Kainos 簽署該備忘錄有利於加強雙方的長期戰略合作關係,實現優勢互補,有助於公司加快開拓海外市場的進程,並將進一步增強公司的整體競爭力。備忘錄擬開展的合作事項符合公司戰略發展需要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account